TabsDetailsBasic DetailsDate Posted: Monday, July 17, 2017Status: CompleteMedical Product: lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenytoinHealth Outcome(s): angioedemaDescription: Modular program-based one-time assessment of incidence rates of angioedema among new users of oral levetiracetam and four other oral anti-epileptic drugs (AEDs). This query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2008 to December 31, 2014. Modular programs are adaptable standardized programs. Results were generated using the Cohort Identification and Analysis (CIDA) tool, version 2.0.8. This query was distributed in October 2015. This report includes data from 15 Data Partners.If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@sentinelsystem.org. Read More Deliverables (1)Mini-Sentinel Modular Program Report: AEDs and AngioedemaAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2008 - December 31, 2014Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Mini-Sentinel Distributed Database (MSDD)
